147 related articles for article (PubMed ID: 21696061)
1. Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection.
Lubetzky M; Auli MJ; Walker J; Leeser D; Kapur S; Hartono C; Dadhania D
Clin Transpl; 2010; ():437-40. PubMed ID: 21696061
[No Abstract] [Full Text] [Related]
2. Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.
Manitpisitkul W; Wilson NS; Philosophe B; Cooper M; Drachenberg C; Kukuruga D; Nogueira J; Haririan A
Clin Transpl; 2010; ():421-8. PubMed ID: 21698839
[No Abstract] [Full Text] [Related]
3. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases.
Cooper JE; Wiseman AC; Chan L
Clin Transpl; 2010; ():415-20. PubMed ID: 21698838
[No Abstract] [Full Text] [Related]
4. Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2010; ():429-36. PubMed ID: 21696060
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
Schwaiger E; Regele H; Wahrmann M; Werzowa J; Haidbauer B; Schmidt A; Böhmig GA
Clin Transpl; 2010; ():391-6. PubMed ID: 21696056
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment.
Sberro-Soussan R; Zuberl J; Suberbielle-Boissel C; Legendre C
Clin Transpl; 2010; ():409-14. PubMed ID: 21696059
[TBL] [Abstract][Full Text] [Related]
7. Targeting alloantibody production with bortezomib: does it make more sense?
Lee I; Constantinescu S; Gillespie A; Rao S; Silva P; Birkenbach M; Leech S; Karachristos A; Daller JA; Sifontis NM
Clin Transpl; 2010; ():397-403. PubMed ID: 21696057
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
[TBL] [Abstract][Full Text] [Related]
9. 1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection.
Shapiro R; Lunz J; Zeevi A; Basu A; Mapara M; Randhawa P; Tan HP; Sharma V; Humar A
Clin Transpl; 2010; ():405-7. PubMed ID: 21696058
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City: an update.
Leyva S; Marino LA; Alberú J; Morales-Buenrostro LE
Clin Transpl; 2010; ():369-82. PubMed ID: 21698837
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib for desensitization of patients on a waiting list for deceased donor kidney transplant: experience in Mexico City.
Marino-Vázquez LA; Leyva S; Alberú J; Morales-Buenrostro LE
Clin Transpl; 2010; ():363-7. PubMed ID: 21696054
[TBL] [Abstract][Full Text] [Related]
12. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS
Clin Transpl; 2009; ():407-14. PubMed ID: 20524306
[No Abstract] [Full Text] [Related]
13. Proteasome inhibition for antibody-mediated rejection.
Everly JJ; Walsh RC; Alloway RR; Woodle ES
Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
Woodle ES; Alloway RR; Girnita A
Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
[TBL] [Abstract][Full Text] [Related]
16. An update on antibody reduction and rejection reversal following bortezomib use: a report of 52 cases across 10 centers.
Everly MJ
Clin Transpl; 2010; ():353-62. PubMed ID: 21696053
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib rescue in refractory acute humoral rejection--report of a case.
Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V
Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
[No Abstract] [Full Text] [Related]
18. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
Pavlakis M
Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
[TBL] [Abstract][Full Text] [Related]
19. Durability of antibody removal following proteasome inhibitor-based therapy.
Everly MJ; Terasaki PI; Trivedi HL
Transplantation; 2012 Mar; 93(6):572-7. PubMed ID: 22262128
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of anti-HLA antibodies via proteasome inhibition.
Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]